PCA (patient controlled analgesia) Chart – adult Education Slide Presentation A presentation prepared by the Pain Interest Group Nursing Issues in association with the Agency of Clinical Innovation Pain Management Network Please direct comments to: March 21, 2013 Emily Edmonds Coordinator State Pain Forms Pain Interest Group Nursing Issues CNC Acute Pain Service Blacktown Hospital Phone: Jenni Johnson Manager Pain Management Network Agency for Clinical Innovation (ACI) Phone: OR

PCA (patient controlled analgesia) chart - adult The PCA prescription and observation chart for adult patients has been developed by a team of experts in the field of acute pain including clinical nurse consultants, anaesthetists and pharmacy representatives. This PCA chart is not suitable for use in paediatric patients. Standardisation of this chart promotes best practice in prescribing, pain assessment and management of adverse effects in those patients receiving an opioid via PCA. 2

Aim of this presentation: This presentation aims to explain  how to use the chart for prescribing a PCA  how to record the administration and discard of drugs used for PCA  how to complete the clinical observations  guidelines on the management of patients receiving PCA including the management of adverse effects 3

PCA chart - adult Booklet format Prescription valid for 4 days Observation pages for 4 days Page 1 Management guidelines 4 Page 1 Page 2 Page 3 Page 2 PCA prescription - PCA program - Neuraxial opioid + PCA -Naloxone prescription Page 3 PCA drug administration - Drug discard -Naloxone administration

Inside pages: Observation pages for up to 4 days PCA chart - adult 5 Inside pages Back page: Clinical Review and Rapid Response Criteria (Between the Flags) Back page

Prescription page: 6 Page 2 Patient label and allergy adverse reactions PCA prescription PCA program - Allows for 2 further changes to the program Record of administration of a neuraxial opioid Prescription for naloxone OR ‘sticker affixed’ stating existing standing order

PCA prescription: 7 Below is an EXAMPLE prescription Refer to hospital PCA policy for local guidelines on PCA prescribing SMITH 22/4/13 PSmith Prescriber to complete patient allergy and ADR section in full Handwrite patient details OR affix patient label (First prescriber to check patient label is correct) Private patients: require a signature from the referring Doctor to the Pain Service PLEASE REFER TO YOUR LOCAL HOSPITAL POLICY FOR PCA DRUG SOLUTIONS

PCA prescription: 8 Below is an EXAMPLE prescription Refer to hospital PCA policy for local guidelines on PCA prescribing A PCA prescription is for one opioid only. When changing from one opioid to another, a new PCA chart must be commenced Morphine 60 mg NIL IV 60 mL 22/04/13 SMITHTSmith PCA prescription to include route, primary drug (e.g. morphine or fentanyl), total amount in mg or microgram and total volume Space is provided for an additional drug to be added if necessary Space provided for pharmacist reconciliation Prescriber’s signature and printed name

PCA program: 9 Below is an EXAMPLE program Refer to hospital PCA policy for local guidelines on PCA prescribing Morphine 1mg 1mg 1 5 mins NIL 10:00 22/04/13 2mg 2 5 mins 1mg 09:0023/04/13 SMITH TSmith JACK S.Jack Morphine 1mg 1 Primary drug and concentration State: mg or microgram per mL Two additional rows are provided for changes to the PCA program PCA bolus dose (state unit of drug and volume) Lockout interval in minutes Background infusion (State mg or microgram and mL per hour) Prescriber’s signature and print name Date and time When changing from one opioid to another, a new PCA chart must be commenced

Neuraxial opioid + PCA: IF a dose of opioid has been administered via the spinal or epidural route during a procedure, AND the patient is to receive a PCA, the following is to be completed 10 Morphine Spinal 200 micrograms 10:00 22/04/13 SMITH TSmith  The frequency of observations (hourly for 6 hours or hourly for 12 hours) must be determined by the medical officer who administered the opioid dose

Naloxone prescription: Naloxone is indicated for SEDATION SCORE 3 (difficult to rouse or unresponsive) OR SEDATION SCORE 2 (constantly drowsy unable to stay awake) and a RESPIRATORY RATE LESS THAN OR EQUAL TO 5 breaths per minute. This section MUST be completed in full OR a sticker affixed which states the standing order PRIOR to any administration of naloxone. 11 Naloxone X micrograms IV 02/04/13 SMITH TSmith 2 -3 minutely

Administration and discard of PCA opioid and administration of naloxone: The fold out section includes space for the documentation of : -PCA commenced -Discard of remaining PCA opioid or drug -Naloxone administration 12 PCA commenced Discard of any remaining PCA opioid or drug Naloxone that may have been administered Page 3

Administration and discard of PCA drug: IF a PCA syringe or bag is empty when the next one is commenced, document ‘NIL’ discarded There are 14 rows provided to record PCA administration and discard Any opioid or drug remaining from a syringe or bag MUST be recorded on the corresponding row from its administration 13 10:00 22/04/13 THall SRose 20:00 22/04/13 BLoh JLucas NIL 20:00 BLoh JLucas 09:00 23/04/13 Plambert TBuckley 15 mL 22/04/13

Record of naloxone administered: 14 08:30 IV 100 micrograms 02/03/13 Plambert TBuckley 08:33 IV 100 micrograms 02/03/13 Plambert TBuckley 08:36 IV 100 micrograms 02/03/13 Plambert TBuckley 08:39 IV 100 micrograms 02/03/13 Plambert TBuckley Naloxone may only be administered when the prescription section of the PCA chart has been completed in full OR if a standing order sticker is affixed

Clinical Review & Rapid Response Criteria: 15 Back page The back page of the PCA chart displays instructions explaining when to make a Clinical Review or a Rapid Response. These instructions incorporate Track and Trigger color zones (from the Between the Flags Program) to promote the recognition of the deteriorating patient associated with the administration of opioids

16 Clinical Review Criteria:

17 Rapid Response Criteria:

18 Page 1 PCA Management Guidelines are provided on the ‘fold-out’ front page of the PCA chart For detailed information regarding PCA prescribing and management refer to local hospital PCA policy or procedure PCA can be ceased according to instructions in the medical record: Date and time prompt provided (Check local policy for use of this prompt) There is space provided for the contact details of your Acute Pain Service or equivalent medical officer who manages PCA

Observations: The PCA chart provides observations for a maximum of 4 days. If the PCA continues beyond 4 days, a new PCA chart must be started and a new prescription written. 19 Inside pages A patient label must be affixed or details written on each page that records observations

Documenting observations: Pain Assessment: ‘R’ for rest ‘M’ for movement 20 RR RR R MMR M M /04/13

Documenting observations: Sedation, respiratory rate & oxygen therapy A sedation score or a respiratory rate in the ‘Red Zone’ requires a Rapid Response to be initiated AND contact the Acute Pain Service (or equivalent medical officer) A sedation score or a respiratory rate in the ‘Yellow Zone’ requires a Clinical Review by the Acute Pain Service (or equivalent medical officer) 21 2L 6L NP FM Oxygen Device Key shown on front PCA Management Guidelines page Assessments must be recorded graphically as shown

Documenting observations: Nausea or vomiting, PCA delivery 22 Ondanestron given  2 mg  10 mg 13 mg 20 mg 25 mg  JS TJ 1 mg 1 mg 1 mg 1 mg NIL     Nausea or vomiting assessment Total primary PCA dose (cumulative) Circle the unit that is being used Background infusion rate (if in use) Total demands / good demands (different pumps use different words to describe how many times the button is pressed) PCA program checked: once per shift and on patient transfer - to ensure the pump program matches the prescription Comments section blank for free text Assessor’s initial

The next two slides detail the front page PCA Management Guidelines 23

24

25

The standardisation of this chart promotes best practice in prescribing, pain assessment and management of adverse effects in those patients receiving an opioid via PCA. Comments or questions can be directed to your implementation officer or the project leaders Emily Edmonds or Jenni Johnson (for contact details see introduction slide) The feedback register can be located on the ACI website: 26